Bronchodilators are central in the treatment of of airways disorders. They are the mainstay of
the current management of chronic obstructive pulmonary disease (COPD) and are critical in …

The β-adrenoceptor agonists (β-agonists) have been used to relieve bronchoconstriction for
at least 5000 years. β-agonists are based on adrenaline and early forms, such as …

Synopsis Formoterol, a selective β 2-adrenoceptor agonist, produces effective
doseproportional bronchodilation, which persists for up to 12 hours, in patients with …

This randomized, double-blind, parallel, multi-center study was designed to determine
whether the addition of salmeterol to existing inhaled corticosteroid therapy provides greater …

Salmeterol xinafoate is a potent and a long-acting β 2-adrenoceptor agonist. It is prescribed
for the treatment of severe persistent asthma and chronic obstructive pulmonary disease …

Purpose To investigate the potential for systemic pharmacokinetic (PK) and
pharmacodynamic (PD) interactions between inhaled fluticasone furoate (FF) and vilanterol …

Background: Salmeterol is a long-acting β 2-agonist which in animal studies has been
shown to possess anti-inflammatory effects on early (EAR) and late (LPR) phase allergic …

According to the duration of bronchodilation, beta-2-agonists are divided into short and long
acting bronchodilators. The bronchodilatory effect of available long acting beta-2-agonists …

Background: Beta-2 agonists are potent inhibitors of mast cell degranulation in vitro.
Intradermally injected they also inhibit mast cell activation in human skin in vivo. To what …

Obese patients are more likely to suffer from severe asthma symptoms and less likely to be
able to control them. In obese patients, there is evidence that shows decreased efficacy of …